3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
84
Colorectal Neoplasms
42
Rectal Neoplasms
40
Carcinoma, Non-Small-Cell Lung
27
Esophageal Neoplasms
24
Esophageal Squamous Cell Carcinoma
23
Stomach Neoplasms
19
Lung Neoplasms
19
Squamous Cell Carcinoma of Head and Neck
17
Colonic Neoplasms
17
Sarcoma
15
Pancreatic Neoplasms
15
Adenocarcinoma Of Esophagus
15
Prostatic Neoplasms
13
Neoplasm Metastasis
13
Neoplasms
12
Head and Neck Neoplasms
12
Ovarian Neoplasms
11
Carcinoma, Hepatocellular
11
Inflammatory Breast Neoplasms
9
Uterine Cervical Neoplasms
8
Urinary Bladder Neoplasms
8
Osteosarcoma
8
Fallopian Tube Neoplasms
8
Central Nervous System Neoplasms
8
Carcinoma, Intraductal, Noninfiltrating
8
Kidney Neoplasms
7
Multiple Myeloma
6
Glioblastoma
6
Carcinoma, Renal Cell
6
Interventions
Sorafenib
5
lenvatinib
2
ledipasvir, sofosbuvir drug combination
2
halofantrine
2
atezolizumab
2
Liver Transplantation
2
Immunotherapy
2
Control Groups
2
Blood Specimen Collection
2
Bevacizumab
2
Antibodies
2
veliparib
1
trifluridine tipiracil drug combination
1
trametinib
1
titanium silicide
1
sintilimab
1
rubitecan
1
repotrectinib
1
pevonedistat
1
pembrolizumab
1
ozanimod
1
linifanib
1
genexol-PM
1
fluorocholine
1
fisogatinib
1
ficlatuzumab
1
durvalumab
1
camrelizumab
1
belinostat
1
bavituximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Liver Diseases
×
Neoadjuvant Therapy
×
Clear all
NCT04727307
2025-09-30
AB-LATE02
University Hospital, Montpellier
Phase 2
Recruiting
202 enrolled